EMEND TRI-PACK CAPSULE

CAPSULE

**IV. DOSAGE AND ADMINISTRATION** EMEND (aprepitant) is available as capsules for oral administration. EMEND is given for 3 days as part of a regimen that includes a corticosteroid and a 5-HT3 antagonist. The recommended dose of EMEND is 125 mg orally 1 hour prior to chemotherapy treatment (Day 1) and 80 mg orally once daily in the morning on Days 2 and 3. The package insert for the co-administered 5-HT3 antagonist must be consulted prior to initiation of treatment with EMEND. EMEND has not been studied for the treatment of established nausea and vomiting. EMEND I.V. 150 mg (fosaprepitant), a lyophilized prodrug of aprepitant for intravenous administration, is also available. EMEND I.V. 150 mg is available as a single dose and is administered on Day 1 only. Recommended dosing for the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy:  Recommended dosing for the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy:  Chronic continuous administration is not recommended. See DRUG INTERACTIONS for additional information on the administration of EMEND with corticosteroids – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_. Refer to the full prescribing information for coadministered antiemetic agents. EMEND may be taken with or without food. No dosage adjustment is necessary based on age, gender, race or Body Mass Index (BMI). No dosage adjustment is necessary for patients with severe renal insufficiency (creatinine clearance <30 mL/min) or for patients with end stage renal disease undergoing hemodialysis. No dosage adjustment is necessary for patients with mild to moderate hepatic insufficiency (Child-Pugh score 5 to 9). There are no clinical data in patients with severe hepatic insufficiency (Child-Pugh score >9).